Impact of adverse drug reaction on quality of life in drug resistant tuberculosis

Siddharth Chatterjee; Arvind Pandey

doi:10.18203/2320-6012.ijrms20240522

Authors

Siddharth Chatterjee Department of Respiratory Medicine, Medanta- the Medicity, Gurugram, Haryana, India
Arvind Pandey Department of Pulmonary Medicine, Surat Municipal Institute of Medical Education and Research, Surat, Gujrat, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20240522

Keywords:

Adverse drug reactions, Drug-resistant tuberculosis, Quality of life

Abstract

Background: India has largest population of drug resistant tuberculosis, the treatment of which is long and full of adverse drug reactions. Despite the ongoing research in clinical and pharmacological aspects, quality of life in drug-resistant tuberculosis remains less explored. This study aims to study the quality of life in drug-resistant tuberculosis patients before and after treatment of the adverse drug reactions.

Methods: This hospital based cross-sectional study done in the at tertiary care center in Surat, from January 2019 to February 2020, enrolling patients above 18 years, with multi-drug/ extensively drug resistant tuberculosis, who suffered > 1 adverse drug reaction after commencing treatment. SF-36 was administered at start of treatment and after treatment of first adverse drug reaction, and scores compared. Paired Student T Test was used for comparison of pre - post scores. p -value < 0.05 is considered statistically significant.

Results: Among the 120 patients studied, majority (87.5%) were had pulmonary tuberculosis. 92.5% and 7.2% were multi-drug resistant and extensively drug resistant respectively. A significant improvement in QOL scores was seen in all 3 domains post treatment of adverse drug reaction- physical domain: After vs. Before: 55.2±6.8 vs. 25.2±4.2; (p-value < 0.0001), mental domain: After vs. Before: 66.8±6.7 vs. 39.4±2.1; (p-value < 0.0001) and social domain After vs. Before: 65.4±5.5 vs. 39.7±2.0; p-value < 0.0001).

Conclusions: Drug-resistant tuberculosis along with its associated adverse drug reactions greatly impacts the quality of life in all domains. However, prevention and effective treatment of such adverse effects, especially in systematic protocolised manner can do wonders in improving the life of these patients.

Metrics

Metrics Loading ...

References

World Health Organization. Global Tuberculosis Report, 2020. Available at: https://www.who.int/publicationsdetailredirect/9789240013131. Accessed on 10 February 2020.

Pai M., Bhaumik S., Bhuyan S.S. India's plan to eliminate tuberculosis by 2025: converting rhetoric into reality. BMJ Glob Health. 2017;2(2).

World Health Organization. Global Tuberculosis Report, 2016. Available at: https://www.who.int/publicationsdetailredirect/9789241565394. Accessed on 10 February 2020.

World Health Organization. Consolidated Guidelines on Drug- Resistant Tuberculosis Treatment, 2019. Available at: https://www.who.int/publications/i/item/9789241550529. Accessed on 10 February 2020.

Seung KJ, Keshavjee S, Rich ML. Multidrug-resistant tuberculosis and extensively drug- resistant tuberculosis. Cold Spring Harb Perspect Med. 2015;5(9):a017863.

Thomas BE, Shanmugam P, Malaisamy M, Ovung S, Suresh C, Subbaraman R, et al. Psycho-socio- economic issues challenging multidrug resistant tuberculosis patients: a systematic review. PLoS One. 2016;11(1):e0147397.

Verma R, Mahor GR, Shrivastva A, Pathak P. Adverse drug reactions associated with first line antitberculosis drugs in a tertiary care teaching hospital: A study of clinical presentations, causality and severity. Asian J Pharm Clin Res. 2014;7(5):140-3.

Jaber AAS, Khan AH, Sulaiman SAS. Evaluation of health-related quality of life among tuberculosis patients in two cities in Yemen. PLoS One. 2016;11(6):48:1-19.

Brown J, Capocci S, Smith C, Morris S, Abubakar I, Lipman M. Health status and quality of life in tuberculosis. Int J Infect Dis. 2015;32:68-75.

Louw J, Peltzer K, Naidoo P, Matseke G, McHunu G, Tutshana B. Quality of life among tuberculosis (TB), TB retreatment and/or TB-HIV co-infected primary public health care patients in three districts in South Africa. Health Qual Life Outcomes. 2012;10(1):77.

Sharma R, Yadav R, Sharma M, Saini V, Koushal V. Quality of life of multi drug resistant tuberculosis patients: a study of North India. Acta Medica Iranica. 2014;52(6):448-53.

Central TB Division, Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, New Delhi. RNTCP Technical and Operational Guidelines for TB Control in India, 2016. Available at: https://tbcindia.gov.in/index1.php?sublinkid=4573&level=2&lid=3177&lang=1. Accessed on 10 February 2020.

Ahmad N, Javaid A, Syed Sulaiman SA, Basit A, Afridi AK, Jaber AA, et al. Effects of multidrug resistant tuberculosis treatment on patients’ health related quality of life: results from a follow up study. PloS one. 2016;11(7):e0159560.

Sineke T, Evans D, Schnippel K, van Aswegen H, Berhanu R, Musakwa N, et al. The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa. Health Qual Life Outcomes. 2019;17(1):94.

Laxmeshwar C, Stewart AG, Dalal A, Kumar AMV, Kalaiselvi S, Das M. Beyond 'cure' and 'treatment success': quality of life of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2019;23(1):73-81.

Dela AI, Tank NKD, Singh AP, Piparva KG. Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: A four year retrospective study. Lung India. 2017;34(6):522-6.

Salehitali S, Noorian K, Hafizi M, Dehkordi AH. Quality of life and its effective factors in tuberculosis patients receiving directly observed treatment short-course (DOTS). J Clin Tuberc Other Mycobact Dis. 2019;15:100093.